FOXO4-DRI is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The most common research dosage for FOXO4-DRI is 5-10 mg per dose, administered 3 consecutive days per cycle via subcutaneous or intravenous injection. Typical cycles run 3-day dosing periods, repeated every 4-6 weeks for 16 weeks total. With a half-life of prolonged by D-retro-inverso modification; specific human half-life not published, timing matters for optimal results.
What Is FOXO4-DRI and Why Does Dosing Matter?
FOXO4-DRI (FOXO4 D-Retro-Inverso peptide) is a Senolytic peptide. Synthetic peptide designed to disrupt FOXO4-p53 protein-protein interaction in senescent cells, with D-retro-inverso modification for protease resistance. Getting the dosage right is critical — too little may produce no measurable effect, while excessive amounts increase risk without proportional benefit.
The standard research dosage for FOXO4-DRI has been established through preclinical studies and community protocols. This guide covers the evidence-backed dosing range, timing, and cycle structure.
What Is the Recommended FOXO4-DRI Dosage?
The most widely used FOXO4-DRI dosage is 5-10 mg per dose, administered 3 consecutive days per cycle via subcutaneous or intravenous injection.
Beginners should start at the lower end of this range and titrate upward only if needed. The half-life of FOXO4-DRI is prolonged by D-retro-inverso modification; specific human half-life not published, which directly determines how often you need to dose to maintain stable blood levels.
For FOXO4-DRI specifically, the 3-day dosing periods, repeated every 4-6 weeks for 16 weeks total cycle length is standard. Longer isn't always better — Senolytic peptide compounds require cycling to maintain receptor sensitivity.
When Should You Dose FOXO4-DRI?
With a half-life of prolonged by D-retro-inverso modification; specific human half-life not published, timing your FOXO4-DRI administration affects peak blood levels. Most protocols call for 3 consecutive days per cycle.
For peptides administered before bed (common with GH-related compounds), the goal is to amplify the natural nocturnal growth hormone pulse. For healing peptides, proximity to the injury site via local injection can improve outcomes.
Calculate Your FOXO4-DRI Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for FOXO4-DRI.
Open Calculator →How Do You Reconstitute FOXO4-DRI?
FOXO4-DRI typically comes as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water — never saline or sterile water, as BAC water contains 0.9% benzyl alcohol that prevents bacterial growth and extends shelf life to 4-6 weeks.
Use our peptide dosing calculator to determine the exact amount of BAC water to add based on your vial size and desired dose per injection.
How Long Should a FOXO4-DRI Cycle Last?
Standard FOXO4-DRI cycles run 3-day dosing periods, repeated every 4-6 weeks for 16 weeks total. This timeframe is based on the compound's mechanism and the time needed to observe measurable effects.
Demonstrated selective senolytic activity in chondrocytes and Leydig cells in peer-reviewed studies. Multiple in vitro and animal model studies confirm selectivity for senescent cells over healthy cells. No completed human trials.
What Side Effects Can Affect Dosing?
Minimal side effects in preclinical studies. Potential transient inflammation during senescent cell clearance as cellular debris triggers immune response. No human safety data published.
If side effects emerge, the first step is typically reducing the dose rather than discontinuing entirely. Most FOXO4-DRI-related side effects are dose-dependent.
How Does FOXO4-DRI Dosing Change When Stacking?
Pairs with Epithalon (telomere maintenance) for comprehensive anti-aging — FOXO4-DRI removes damaged senescent cells while Epithalon maintains telomere length in healthy cells.
When stacking, some researchers reduce individual peptide doses by 20-30% since synergistic effects mean full doses of each aren't always necessary.
What Is the Bottom Line on FOXO4-DRI Dosing?
Start at 5, dose 3 consecutive days per cycle, and run cycles of 3-day dosing periods, repeated every 4-6 weeks for 16 weeks total. Monitor your response and adjust within the established range.
Source matters — always use research-grade FOXO4-DRI from vendors with third-party COA testing. Underdosed or contaminated products are the most common reason for poor results.
Related Reading
- FOXO4-DRI Benefits
- FOXO4-DRI Side Effects
- FOXO4-DRI Stacking Guide
- FOXO4-DRI Cycle Guide
- FOXO4-DRI Research
- Epithalon Complete Guide
Research-Grade Sourcing
If you're going to research FOXO4-DRI, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is FOXO4-DRI?
FOXO4-DRI (FOXO4 D-Retro-Inverso peptide) is a Senolytic peptide. Synthetic peptide designed to disrupt FOXO4-p53 protein-protein interaction in senescent cells, with D-retro-inverso modification for protease resistance. It is researched for senescent cell elimination, improved tissue function, cartilage regeneration, testosterone restoration, anti-aging.
What is the recommended FOXO4-DRI dosage?
Common dosages: 5-10 mg per dose administered 3 consecutive days per cycle via subcutaneous or intravenous injection. Cycle length: 3-day dosing periods, repeated every 4-6 weeks for 16 weeks total. Half-life: prolonged by D-retro-inverso modification; specific human half-life not published. Use our peptide calculator for exact reconstitution math.
What are the side effects of FOXO4-DRI?
Minimal side effects in preclinical studies. Potential transient inflammation during senescent cell clearance as cellular debris triggers immune response. No human safety data published.
Is FOXO4-DRI safe?
FOXO4-DRI has shown a preliminary safety profile in research. Not FDA-approved. Research use only. All research should follow appropriate safety protocols.